We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc
ARNA

Delisted

ARNA was delisted on the 10th of March, 2022.

Back to rankings

125 hedge funds and large institutions have $978M invested in Arena Pharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 40 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more call options, than puts

Call options by funds: $47.9M | Put options by funds: $16.6M

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

34% more capital invested

Capital invested by funds: $731M → $978M (+$247M)

32% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 19

13% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 40

5% more funds holding

Funds holding: 119 → 125 (+6)

Holders
125
Holders Change
+6
Holders Change %
+5.04%
% of All Funds
2.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
25
Increased
45
Reduced
40
Closed
19
Calls
$47.9M
Puts
$16.6M
Net Calls
+$31.3M
Net Calls Change
+$13.6M

Top Buyers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$15.3M
2
DM
Deerfield Management
New York
+$12.8M
3
CS
Credit Suisse
Switzerland
+$7.98M
4
Citadel Advisors
Citadel Advisors
Florida
+$7.45M
5
Invesco
Invesco
Georgia
+$6.3M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$9.39M
2
BIM
Bogle Investment Management
Massachusetts
-$8.96M
3
State Street
State Street
Massachusetts
-$8.76M
4
NI
Numeric Investors
Massachusetts
-$7.03M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
126
Polar Capital
United Kingdom
– -$3.83M -150,000 Closed
Mirae Asset Global Investments
127
Mirae Asset Global Investments
South Korea
– -$2.26M -88,572 Closed
SCM
128
Sio Capital Management
New York
– -$1.84M -72,086 Closed
NFA
129
Nationwide Fund Advisors
Ohio
– -$988K -38,751 Closed
OAM
130
Oxford Asset Management
United Kingdom
– -$803K -31,469 Closed
CLCM
131
Crawford Lake Capital Management
New Jersey
– -$594K -23,281 Closed
QIM
132
Quantitative Investment Management
Virginia
– -$433K -17,000 Closed
DCM
133
Dupont Capital Management
Delaware
– -$422K -16,568 Closed
Wolverine Trading
134
Wolverine Trading
Illinois
– -$225K -8,842 Closed
BRF
135
B. Riley Financial
California
– -$204K -8,010 Closed
TRCT
136
Tower Research Capital (TRC)
New York
– -$26K -1,029 Closed
NFG
137
Next Financial Group
Texas
– -$12K -456 Closed
CG
138
Cutler Group
California
– -$7.09K -249 Closed
Toronto Dominion Bank
139
Toronto Dominion Bank
Ontario, Canada
– -$2K -75 Closed
SFG
140
SevenBridge Financial Group
Pennsylvania
– -$1K -30 Closed
FDCDDQ
141
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$638 -25 Closed
BWM
142
Baystate Wealth Management
Massachusetts
– -$1K -5 Closed
SWP
143
Stratos Wealth Partners
Ohio
– +$285 +10 New
2 3 4 5
6

ARNA Hedge Fund Activity: Q4 2017 in Review

125 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2017, worth a combined $978M — up 34% from $731M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ARNA positions and 19 closed out — a net gain of 6 holders — while 45 added to existing stakes and 40 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $15.3M. The largest seller was Renaissance Technologies, cutting an estimated $9.39M.

  • 125 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2017, up from 119 in Q3 2017.
  • Funds reported $978M of Arena Pharmaceuticals Inc stock for Q4 2017, up 34% quarter-over-quarter.
  • 25 funds opened new Arena Pharmaceuticals Inc positions in Q4 2017 and 19 closed out, a net change of +6 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q4 2017 was Alyeska Investment Group, an estimated $15.3M added.
  • The largest Arena Pharmaceuticals Inc seller in Q4 2017 was Renaissance Technologies, an estimated $9.39M sold.

Based on aggregated 13F filings for Q4 2017.